- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Lilly to submit obesity pill after hitting goal in third late-stage trial | ||
| Di | Why an FDA decision on Stealth's Barth drug could ripple through the rare disease field | ||
| Di | RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial | ||
| Mo | Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales | ||
| Mo | FDA suspends license for Valneva's chikungunya shot | ||
| Mo | AbbVie wagers more than $1B on Gilgamesh's psychedelic drug | ||
| Mo | Drugs from China are reshaping biotech. Track the licensing deals here. | ||
| Fr | FDA cancels adcomm on Biohaven drug; Catalent lays off staff | ||
| Do | US, EU agree to terms of framework trade pact | ||
| Do | FDA approves Ionis' hereditary angioedema drug | ||
| Do | Gilead dives into 'in vivo' cell therapy with $350M buyout of Interius | ||
| Do | Sarepta pushes off debt payments in bid to regain financial footing | ||
| 20.08. | Xoma, a drug royalty specialist, buys another 'zombie' biotech | ||
| 20.08. | Lilly searching for new neuro chief as White set to retire | ||
| 20.08. | Rocket can resume gene therapy trial after FDA lifts hold | ||
| 20.08. | MAHA may take aim at pharma DTC ads | ||
| 19.08. | Viking shares sink as obesity pill misses expectations in key study | ||
| 19.08. | CSL to separate vaccine business, cut jobs | ||
| 19.08. | PTC Therapeutics drug for Friedrich's ataxia rejected; Lilly sells nearly $7B in bonds | ||
| 19.08. | Omega's Otello Stampacchia on the 'reset' changing biotech for the better | ||
| 18.08. | Stealth resubmits rare disease drug to FDA | ||
| 18.08. | Kennedy's mRNA cuts could set US science back, experts warn | ||
| 18.08. | Reunion's psychedelic drug headed to late-stage testing | ||
| 18.08. | Novo's Wegovy becomes first GLP-1 drug approved for MASH | ||
| 18.08. | The unexpected medication that could revolutionize the treatment of Alzheimer's disease |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .